When Will Genomic Medicine Become As Common As Antibiotics?

Posted on April 29, 2015 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

I’m completely and utterly fascinated by the work that so many companies are doing with genomic medicine. I think that’s a good thing since I believe genomic medicine is just now starting to make its way into mainstream medicine. Plus, over the next couple years, genomic medicine is going to be a huge part of what every doctor does in healthcare. Maybe it won’t be as common as the antibiotic (what is?), but it will be extremely important to healthcare.

With that in mind, I’ve been devouring this whitepaper on the evolving promise of genomic medicine. It offers such a great overview of what’s happening with genomic medicine.

For example, they offer a great list of reasons why genomic medicine has become so important today: descreased cost of sequencing, speed of sequencing, availability of genomic tests, ways the genome can be used, reimbursement by payors, etc. That’s such a powerful cocktail of improvements. Does anyone doubt that widespread genomic medicine is near?

I also love how the whitepaper highlights the three pillars of genomic medicine: sequencing, translational medicine and personalized healthcare. That provides a great framework for starting to understand what’s happening with genomic medicine. Plus, the whitepaper offers these place where we’re seeing real benefits in healthcare: prediction of drug response, diagnosis of disease, and identification of targeted therapies. While much of this is still being tested, I’m excited by its progress.

I still have a lot to learn about genomic medicine, but the evolving promise of genomic medicine whitepaper has me even more interested in what’s happening. I’d be interested to hear what companies you think are most interesting in the genomic medicine space.